Gerresheimer stock steadies as AGM and Q1 2026 numbers frame the outlook
Published on 09/01/2026 at 07:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer stock (ISIN DE000A0LD6E6) enters September 2026 with a stable late-August price reference and a fresh set of first-quarter 2026 figures that give investors a clearer view of the company’s momentum. Per recent reporting dated August 28, 2026, Gerresheimer AG shares traded at EUR 26.50 on Tradegate, with preliminary Q1 2026 revenue of EUR 524 million and adjusted EBITDA of EUR 66 million anchoring the fundamental story for the new financial year. The virtual annual general meeting on August 31, 2026 provides an additional catalyst as management outlines strategy and capital allocation against that backdrop.
AGM timing and Q1 2026 fundamentals
A key near-term milestone for Gerresheimer AG is its virtual annual general meeting, which is scheduled for August 31, 2026, giving shareholders a defined date to hear directly from management on the outlook for the remainder of 2026. A recent German agenda overview lists the Gerresheimer AGM at 10:00 a.m., underlining that corporate governance and strategy are front and center as investors process the latest quarterly metrics.
The fundamental anchor for this meeting is the first-quarter 2026 update. Recent reporting on Gerresheimer’s Q1 2026 performance cites preliminary revenue of EUR 524 million for the quarter, marking the company’s latest top-line marker for the new fiscal year. Adjusted EBITDA for the same period was EUR 66 million, giving a sense of profitability and operational leverage as Gerresheimer continues to position itself as a specialist in pharmaceutical and healthcare packaging.
Cash flow trends are an important part of the story. In the first quarter of 2026, free cash flow was reported at minus EUR 32 million. While this is still negative, it represents a clear improvement compared with minus EUR 141 million in the first quarter of 2025, a positive swing of EUR 109 million year over year. That quantified change suggests that Gerresheimer is moving toward a healthier cash-flow profile even as it invests, and it gives investors a concrete basis to evaluate whether management’s capital spending and working-capital initiatives are gaining traction.
Analyst views and price-target context
The market’s perception of Gerresheimer is also shaped by external research. On August 28, 2026, an analyst update kept Gerresheimer AG rated at Overweight with a price target of EUR 46.00, signaling that at least one research provider still sees upside potential from current trading levels. A rating overview shows the Overweight stance and the EUR 46.00 target alongside an indicated market price of EUR 27.84 on the day of the update, which implies a theoretical upside of more than 60 percent if the target were eventually reached.
Consensus data deepen that picture. A same-day analyst summary indicates that one analyst currently recommends the share as a Buy, while five advise holding the position. The average price target across this small group stands at EUR 30.43, compared with a reported XETRA price of EUR 28.12, implying expected upside of EUR 2.31 per share or roughly 8 percent if the consensus view plays out. The same consensus snapshot highlights that the six-month rating trend is categorized as Buy, even though the near-term consensus is relatively cautious, with a majority of Hold recommendations.
For investors, the combination of an Overweight rating with a higher individual target and a more moderate consensus level illustrates how views on Gerresheimer diverge. The EUR 46.00 target sits clearly above the EUR 30.43 average, implying a substantial gap between the most optimistic expectations and the broader analyst community. That discrepancy can become an important factor during the AGM and subsequent presentations, as management’s commentary on growth, margins and cash flow will help market participants decide which scenario appears more plausible.
International trading and performance markers
Gerresheimer AG is primarily listed in Germany, but the shares also trade over the counter in the United States under the symbol GRRMF. A recent US-market overview shows the OTCMKTS listing with a quote of $32.20 for GRRMF as of August 28, 2026. That same overview notes that Gerresheimer’s stock traded at $36.83 on January 1, 2026, implying that the US-traded shares have declined by 12.6 percent year to date, a concrete performance marker for investors considering the name in a global health-care and medical-supplies context.
The US quote also gives a sense of trading dynamics. As of August 28, 2026, GRRMF shows a 52-week range between $19.17 and $33.35, signaling that the latest $32.20 level is close to the upper end of the recent trading corridor. Daily volume on that date is listed at 62 shares, versus an average of 242 shares, underlining that the OTC line is relatively illiquid compared with main-market German trading. For portfolio managers, illiquidity can amplify price swings, so the balance between the German listing and the US OTC trading line is worth monitoring.
In the German market, late-August data point to Gerresheimer AG trading at EUR 26.50 on Tradegate on August 28, 2026 at 10:25 p.m. ET, with a modest gain of 0.15 percent on the day. A recent market snapshot uses that level as a reference point heading into the AGM window. While this is not current intraday data for September 1, 2026, it offers a recent closing marker that investors can use alongside more up-to-date quotes on their brokerage platforms to gauge whether the stock has moved materially after the AGM.
Packaging solutions for pharma and biotech
Beyond near-term market moves and analyst views, Gerresheimer’s business model revolves around specialized packaging and delivery systems for the pharmaceutical and biotech industries. The company is known for manufacturing glass and plastic containers, vials, syringes and other primary packaging solutions that meet stringent regulatory standards for drug safety, shelf life and patient usability. These products are critical for injectable medications, respiratory therapies and a wide range of other treatments where dosage precision and sterility are required.
Within this portfolio, one representative product area is ready-to-fill glass vials for vaccines and biologics. Gerresheimer supplies drug manufacturers with standardized vials that can be integrated into automated filling lines, supporting rapid scale-up when demand for a particular vaccine or biologic therapy increases. The ability to deliver high-quality vials with consistent dimensions and material properties helps pharmaceutical customers reduce the risk of contamination and ensures that labeling, transportation and storage can be handled efficiently across different geographies.
Another important segment is prefillable syringes and injection systems. These devices are designed to improve dosing accuracy and patient comfort, especially for chronic conditions where self-injection at home is part of the treatment plan. By combining precision engineering with materials that are compatible with complex biologic formulations, Gerresheimer aims to provide drug companies with devices that minimize interactions between the drug and the container while also reducing breakage and leakage during transport.
Gerresheimer’s focus on innovation in packaging often translates into close collaboration with customers on custom solutions. For example, when a biotech firm develops a novel monoclonal antibody therapy, the stability of the molecule can depend heavily on the surface characteristics of the container and the presence of coatings or additives. In such cases, Gerresheimer engineers may work with the customer’s formulation scientists to adjust glass composition, surface treatments or syringe design to improve long-term stability and reduce the risk of aggregation, enabling a longer shelf life and more flexible distribution.
The company’s capabilities also extend to plastic packaging, including inhaler components, ophthalmic dropper bottles and other devices used in respiratory and eye-care therapies. These products must accommodate both mechanical and chemical requirements: mechanical robustness for repeated use or actuation, and chemical resistance to prevent the polymer from absorbing or reacting with the medication. By leveraging injection-molding expertise and quality-control systems, Gerresheimer seeks to ensure that each component meets regulatory expectations from agencies like the European Medicines Agency and the US Food and Drug Administration.
From an investor perspective, the breadth of Gerresheimer’s packaging solutions means that the company is exposed to multiple therapeutic areas and customer segments, which can help diversify revenue. However, it also implies ongoing capital expenditure to maintain and upgrade production lines, quality laboratories and clean-room facilities, as well as continuous R&D spending to keep up with emerging drug formats such as cell and gene therapies. This structural context makes the Q1 2026 cash-flow improvement particularly relevant, because it suggests the company may be freeing up more internal resources to fund growth initiatives without overreliance on external financing.
Current price context and investor takeaways
Based on the latest US-market overview for Gerresheimer’s OTC listing, GRRMF shares were quoted at $32.20 as of August 28, 2026. That level, combined with the earlier late-August German reference price of EUR 26.50, indicates that Gerresheimer stock is trading comfortably within its 52-week range but below the most optimistic price targets that some analysts have articulated. For investors, the key question is whether the combination of improving cash flow, solid Q1 2026 revenue and EBITDA figures, and an upcoming AGM is sufficient to close part of the gap between current prices and the higher target levels.
As of August 28, 2026, 4:00 p.m. ET, Gerresheimer’s GRRMF line on OTCMKTS stood at $32.20. That quote serves as a recent benchmark for US investors until new intraday data for September 1, 2026 become available on trading platforms. Given the year-to-date decline of 12.6 percent from the $36.83 level on January 1, 2026, the stock still reflects a period of adjustment, possibly tied to broader market rotations in healthcare or to company-specific factors that will be clearer once more quarterly data are published. Investors who follow Gerresheimer closely will therefore pay particular attention to the messaging and detail at the AGM and to subsequent Q2 and Q3 releases, where trends in revenue, margins and free cash flow can confirm whether the improving first-quarter picture is sustainable.
Go deeper
More on Gerresheimer stock, including future quarterly updates and investor presentations, can be found via the company’s investor relations portal and dedicated market-data pages that track both the German listing and the US OTC symbol.
Investor Relations
Gerresheimer AG maintains an investor-relations section where shareholders can access financial reports, presentations and AGM materials. This hub typically provides detailed information on revenue segments, regional performance and strategic initiatives such as capacity expansions or acquisitions.
Fact box
Company: Gerresheimer AG
ISIN: DE000A0LD6E6
Ticker: GXI / GRRMF
Exchange: Frankfurt / OTCMKTS
Price (as of August 28, 2026, 4:00 p.m. ET): $32.20 USD
Market cap: data based on recent market overviews
Sector / Industry: Healthcare / Pharmaceutical packaging and delivery systems
Index membership: SDAX
Amazon
Selected Gerresheimer packaging products, such as pharmaceutical-grade containers, may be available via distribution partners on general e-commerce platforms, but core business-to-business solutions are typically procured directly by pharmaceutical and biotech companies through contractual supply agreements.
